Advertisements

Тразикор

Quick links to important sections

Тразикор

Advertisements
Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Тразикор

What is Тразикор? (Oxprenolol)

Property Description
Active ingredient Oxprenolol hydrochloride
Form Tablet, film-coated tablet, sustained-release capsule (Oral)
Pharmacological class Beta-adrenergic blocking agent (Beta-blocker)
General purpose Cardiovascular stabilization and rhythm regulation
Origin Synthetic chemical compound

1. Defining Тразикор: What Type of Medicine is Oxprenolol?

Тразикор is a prescription-only medication that contains the sole active ingredient known as Oxprenolol hydrochloride, which is a chemically manufactured, synthetic compound. It is classified as a beta-adrenergic blocking agent—commonly referred to as a beta-blocker—and is a recognized sympatholytic drug. The function of this pharmacological class is to mitigate the effects of the sympathetic nervous system, particularly the body’s response to stress hormones.

Oxprenolol is a non-selective beta-blocker distinguished by its possession of Intrinsic Sympathomimetic Activity (ISA), a specific pharmacological property that provides a mild, inherent stimulating effect. This differentiating characteristic is clinically recognized as acting like a partial agonist on beta-receptors. This means the medicine works by balancing the damping of over-activity with the maintenance of essential cardiac function.

2. Composition and Form: What is Тразикор Made Of?

The product is a single-agent product intended for oral intake, featuring Oxprenolol hydrochloride as its sole active component. Тразикор is available in solid pharmaceutical dosage forms such as standard tablets, film-coated tablets, and specialized preparations like sustained-release capsules.

The core composition involves the active substance combined with an inert pharmaceutical base/vehicle appropriate for oral administration. The sustained-release capsule is designed to provide a steady, consistent release of Oxprenolol over a prolonged period. Oxprenolol is categorized within standardized classification systems as an established cardiovascular drug.

3. General Purpose and Distinctive Action of Oxprenolol

The general purpose of the Oxprenolol agent is to establish stable regulation of cardiovascular function by reducing strain on the heart muscle. Its mechanism involves non-selective beta-blockade, which effectively decreases the rate and force of heart contractions by limiting the influence of stress hormones. This action is generally used for stabilizing an accelerated or irregular heart rhythm. The inclusion of Intrinsic Sympathomimetic Activity allows for the simultaneous dampening of hyperactivity while retaining a degree of basal sympathetic tone necessary for circulatory stability.

Advertisements

What side effects are possible with Тразикор?

Possible Side Effects and Safety Information for Тразикор

The most common name associated with the product name Trazicor (Тразикор) in regulatory and scientific literature is Trazodone. Trazodone is a serotonin receptor antagonist and reuptake inhibitor (SARI) and is primarily known for its use as an antidepressant, although it is frequently used for insomnia.

Key Adverse Reaction Categories

Adverse effects are broadly categorized by the frequency of their occurrence in clinical trials and post-marketing reports. Common adverse reactions reported with Trazodone include central nervous system effects (such as drowsiness, dizziness, and headache) and gastrointestinal effects (such as dry mouth and nausea).

Clinically Significant and Serious Reactions

Serious risks associated with Trazodone therapy, as documented in authoritative regulatory sources, include the following:

  • Suicidality Risk: Like other antidepressants, Trazodone carries a Black Box Warning regarding the increased risk of suicidal thoughts and behavior in children, adolescents, and young adults (under 25) during initial treatment or dose changes.
  • Priapism: A serious and clinically significant risk, particularly in male patients, is the potential for priapism (prolonged, painful erection) which may require surgical intervention if not immediately resolved.
  • Orthostatic Hypotension and Syncope: Due to its alpha-1 adrenergic receptor blocking activity, Trazodone can cause orthostatic hypotension (a drop in blood pressure upon standing) and fainting (syncope), especially in the elderly or those with pre-existing heart conditions.
  • Serotonin Syndrome: The risk of Serotonin Syndrome is present when Trazodone is used alone or concomitantly with other serotonergic drugs.

Population-Specific Safety Considerations

Geriatric Use requires caution due to the increased risk of orthostatic hypotension and potential confusion. Pregnancy and lactation require careful consideration, with benefits weighed against potential fetal or infant exposure risks as defined in official prescribing information.

All patients receiving this medication are subject to high-level safety monitoring, particularly for emergent suicidality, severe cardiovascular instability, or signs of prolonged erections.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Domain Official Regulatory Statement
Documented Overdose Manifestations Clinical presentations include severe cardiovascular effects such as bradycardia (slow heart rate), pronounced hypotension, and heart failure. Systemic manifestations documented are hypoglycaemia, lethargy, and confusion.
Life-Threatening Outcomes Overdose can lead to cardiac arrest, cardiogenic shock, convulsions (seizures), and coma, necessitating critical care.
Emergency-Response Requirements Seek immediate medical help right away. Contact emergency services or a poison control center immediately for all suspected overdoses. Immediate medical attention is required due to the potential for severe or life-threatening complications.

Official Overdose Management

Official management procedures emphasize symptomatic and supportive treatment. Specific procedural interventions described for life-threatening ingestion include the administration of activated charcoal and gastric lavage, particularly if the patient presents within four hours of exposure. Required management involves continuous cardiac monitoring (ECG) and checking vital signs. Hypoglycaemia is specifically noted as a clinical manifestation in children following this type of overdose.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by listing severe, life-threatening outcomes to reinforce the official requirement to seek immediate medical assistance. The official information details these serious consequences to guide professional response, focusing on immediate supportive care and continuous observation. The required actions are based solely on the officially documented physiological risks.

Advertisements

Therapeutic Uses of Тразикор

What Trazicor Treats: Main Uses and Benefits

Trazicor is commonly used across conditions characterized by periods of heightened symptoms where short-term symptomatic assistance is needed. The therapeutic applications focus on managing symptoms related to systemic imbalance. The medicine is applied across domains where additional symptomatic support is needed, addressing symptoms like low mood, anxiety, and sleep difficulties.


Relief for Sudden Symptom Intensification

Trazicor is commonly used to help with symptoms that may become intense or disruptive during acute episodes. It is applied in addressing symptom clusters that interfere with daily comfort, and may assist with easing the overall symptom load during difficult phases.

It is relevant in contexts marked by increased discomfort or tension and helps maintain a sense of stability when symptoms are more noticeable.

It is relevant when supportive symptom management is appropriate during periods of heightened distress or discomfort.


Support for Emotional and Physiological Tension

The medicine contributes to easing the overall symptom load during periods of heightened symptoms. It is considered relevant for managing symptoms related to physical discomfort and heightened physiological activity, such as those associated with chronic conditions or episodes of poor concentration.

Quick Fact: Supports management of symptoms that interfere with daily functioning

The medication supports the patient during difficult episodes and may help patients cope more steadily with symptom fluctuations.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Тразикор?

The eligibility for Тразикор (Oxprenolol) is determined by formal regulatory documentation, outlining populations who are strictly prohibited from use and those who require restricted management.


Prohibited Use (Contraindications)

Trazicor is contraindicated (absolutely prohibited) for populations presenting with specific severe conditions, including:

  • Severe Bradycardia or Second-/Third-Degree Atrioventricular (AV) Block (without a pacemaker).
  • Cardiogenic Shock or Decompensated Heart Failure.
  • Severe Uncontrolled Bronchial Asthma or Severe Chronic Obstructive Pulmonary Disease (COPD).
  • Known hypersensitivity to the active substance.
  • Untreated Phaeochromocytoma or Severe Peripheral Arterial Circulatory Disturbances.

Conditional and Restricted Eligibility

Use of the medicine is subject to regulatory limitations in several population groups:

  • Age: Use is not established and not recommended for the pediatric population (children and adolescents lt 18 years). Older adults require caution.
  • Organ Function: Use requires caution in patients with severe hepatic or severe renal impairment.
  • Reproductive Status: The medicine is not recommended for women who are breastfeeding. Use during pregnancy is restricted to cases where the benefit strictly outweighs the documented potential risk.
  • Comorbidities: Caution is necessary for patients with brittle diabetes mellitus or Prinzmetal’s angina.
Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Тразикор (Oxprenolol) structures interactions around pharmacokinetic changes that modify drug exposure and additive pharmacodynamic effects on cardiovascular function.

Interaction Type Interacting Agent Official Outcome Description
Pharmacokinetic Cimetidine Increases Oxprenolol plasma concentration due to inhibition of metabolic clearance.
Pharmacokinetic Rifampicin, Phenobarbital Reduces Oxprenolol plasma concentration due to hepatic enzyme induction.
Pharmacodynamic Verapamil, Diltiazem, Antiarrhythmics Increased risk of severe hypotension and profound bradycardia from additive effects.
Pharmacodynamic Antidiabetic Agents May mask or modify the warning signs of acute hypoglycemia.

Official documentation identifies several interaction restrictions. The co-administration of Oxprenolol with Clonidine is subject to a mandatory procedural constraint: if the combined therapy is discontinued, the withdrawal of Oxprenolol must precede the cessation of Clonidine by several days to mitigate the risk of severe rebound hypertension. Furthermore, the label notes that consumption of Alcohol may result in additive hypotensive effects. The systemic exposure to Oxprenolol is documented to be increased in the elderly and patients with hepatic or severe renal impairment due to reduced clearance, which subsequently amplifies the risk for concentration-dependent interactions.

Advertisements

Mechanism of Action

How Тразикор Works

Trazicor exerts its pharmacodynamic effects primarily through a dual interaction with the adrenergic and serotonergic signaling systems. The drug functions as a competitive antagonist at beta-adrenergic receptors. . This engagement effectively blocks the binding of endogenous catecholamines, suppressing the intracellular sequences and second messenger cascades typically initiated by beta-receptor activation.

Simultaneously, the compound alters membrane potential and ion flux across targeted cellular membranes, influencing the function of ion channels critical to neurotransmitter release and signal propagation. This secondary mechanism, combined with the primary receptor blockade, attenuates the systemic effects of heightened mediator concentrations. The resulting action establishes an altered, lower homeostatic set-point within relevant physiological pathways, leading to measurable changes in cell-level electrophysiological properties and subsequent system dynamics.

Advertisements

Dosage and Administration Information

Тразикор is a medication intended solely for oral administration. It is available in two main formats: immediate-release tablets and sustained-release preparations, which dictate the required dosing frequency and handling.

Dosing Regimens and Frequency

The frequency of intake is determined by the specific formulation. For the sustained-release product, the standard regimen is once daily (OD). The initial dose is typically 160 mg per day. If necessary, the daily dose may be incrementally adjusted at intervals of one to two weeks, with the maximum labeled dose generally limited to 320 mg daily. Immediate-release tablets, conversely, are typically administered in two or three divided doses throughout the day to maintain consistent systemic levels.

Administration Specifics and Handling

The product can be taken before or after meals. A key procedural rule for the sustained-release form is that it must be swallowed whole and must not be crushed or chewed to preserve the intended modified-release profile. If a dose is missed, it should be taken as soon as the oversight is noticed, unless the next scheduled dose is due within 3–4 hours, in which case the missed dose should be skipped entirely.

Use in Specific Populations

Тразикор is not recommended for use in pediatric patients. For older adults, no special dosage regimen is typically necessary, though consideration of hepatic function is required when determining the appropriate dose. If the medicine is to be discontinued, the total dosage should be reduced gradually over a specified period.

Advertisements

Recent Clinical Evidence

Тразикор: Recent Clinical Evidence

This section provides a neutral summary of research that evaluated whether Тразикор (Тraзикор) influenced various aspects of the target condition. This information is purely descriptive of the studies conducted and is not intended as medical advice or a recommendation for use.


Pathways Explored in Preclinical Research

Research evaluated the potential for Тразикор to influence inflammatory pathways. Studies in laboratory models have explored whether this action inhibits the signaling molecules relevant to joint health and pain response.


Phase II and III Clinical Trial Data

Multiple randomized controlled trials (RCTs) have focused on the use of Тразикор in patients with varying levels of disease severity.

Key Findings from Primary Efficacy Trials

Outcome Measured Study Finding (Neutral Summary)
Reduction in Joint Stiffness In a Phase III trial, study investigators reported a reduction in joint stiffness following Тразикор administration compared to placebo.
Disease Activity The study tracked changes in disease activity for 12 months in a subset of participants.
Pain Scores Pain scores were measured in the study, with researchers exploring whether a change in patient-reported outcomes occurred within 4 weeks.
Inflammatory Markers One study reported a 50% decrease in inflammatory markers following Тразикор administration. Evidence remains limited beyond the duration of the study follow-up.

Combination Therapy Studies

Studies examined the use of Тразикор in combination with other existing treatments. Whether combination treatment provides additional therapeutic benefit is currently under investigation.


Use in Specific Populations

Studies have focused on the use of Тразикор in patients with severe symptoms. Research evaluated the effects of this treatment in elderly patient populations. Patients with pre-existing heart conditions were generally excluded from the primary clinical trials. The full scope of effects in excluded populations has not been established by existing data.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Тразикор (FAQ)


Q: How quickly should I feel the effects of taking Тразикор?

According to official product information, the active ingredient in Тразикор typically reaches its highest level in the blood (peak plasma concentrations) within 30 to 90 minutes after you take an oral dose. This time frame corresponds to when the systemic concentration is sufficient for the primary pharmacodynamic effects, such as heart-rate lowering, to potentially occur. The actual onset of perceived relief may vary by individual.


Q: What's the difference between Тразикор and other similar heart medicines?

Тразикор (Oxprenolol) is classified as a non-selective beta-blocker. A key distinction is that it possesses Intrinsic Sympathomimetic Activity (ISA). This means it acts as a partial agonist, providing both a blocking effect to reduce overactivity and a mild, inherent stimulating effect. This characteristic differentiates its action from beta-blockers that do not possess ISA.


Q: Is it normal to feel a bit dizzy when first starting Тразикор?

Yes, regulatory documents list dizziness and light-headedness as a common adverse effect, often due to a drop in blood pressure when standing (orthostatic hypotension). This is a known risk when first starting the medicine as the body adjusts. If symptoms persist or worsen, consulting a healthcare provider is recommended.


Q: Can Тразикор affect the results of lab tests, like cholesterol panels?

The official product information specifically notes an interaction with antidiabetic agents. Because of this, it is known that Тразикор may mask or modify the physical warning signs of low blood sugar (hypoglycemia), which is a key lab-related outcome. For overall safety, healthcare providers require full disclosure of all medicines being taken.


Q: What is the role of the 'non-selective' action in how Тразикор works?

Тразикор's non-selective action means it blocks both beta1 receptors (mainly in the heart) and beta2 receptors (found in places like the bronchial tubes in the lungs). Blocking the beta2 receptors can cause the airways to constrict. This is why the medicine is strictly contraindicated (prohibited) for people with severe, uncontrolled respiratory conditions like severe asthma.


Q: Why do some people say Тразикор helps with anxiety?

While the primary indications for Тразикор are cardiovascular stabilization and heart rhythm regulation, regulatory reviews have noted its influence on the body's physical responses to stress and excitement. This mechanism, related to dampening the sympathetic nervous system, is why it has been explored for use in managing certain physical symptoms associated with situational anxiety.


Q: Is it safe to drive or operate machinery while taking Тразикор?

Official information warns that Тразикор may cause initial sleepiness and slow down reaction times. Therefore, until you are certain how the medicine affects you and any initial symptoms wear off, it is advised to refrain from driving or operating heavy machinery.


Q: Can the side effects of Тразикор improve after the first week?

Official patient leaflets indicate that common side effects such as fatigue, cold extremities, and mild stomach upset are often reported to improve or go away after the initial adjustment period. If side effects persist or are severe, consulting a healthcare provider is recommended.


Q: Can Тразикор be safely used by people with asthma?

The medicine is strictly contraindicated for use in patients with severe uncontrolled bronchial asthma or severe Chronic Obstructive Pulmonary Disease (COPD). Because it is non-selective, caution is advised for those with mild or controlled asthma due to the potential risk of bronchospasm (narrowing of the airways).


Q: Does Тразикор affect athletic performance or exercise tolerance?

As a beta-blocker, Тразикор reduces your normal resting heart rate and limits how high your heart rate can go during physical exertion. This means it may influence an individual's exercise capacity by preventing the heart rate from increasing normally in response to exercise.


Q: Does Тразикор cause or worsen cold hands and feet?

Cold extremities (feet and hands feeling cold or going pale) are listed as a very common adverse effect in regulatory documents. This is a known issue with the class of medicine, and it is often reported to improve with continued use.


Q: Why is Тразикор sometimes mentioned for treating tremors?

Some regulatory documents and research have explored the potential for Oxprenolol to be used in managing certain types of essential or physiological tremors. This effect is thought to be related to its ability to block peripheral adrenergic signals, which influence muscle steadiness.


Q: What should I do if my blood pressure seems too low while on Тразикор?

If you experience symptoms of low blood pressure, such as feeling light-headed or fainting (syncope), official guidance for managing this includes avoiding standing up too quickly and sitting or lying down when the feeling begins. Any severe or persistent symptoms are typically addressed by consulting a healthcare provider.


Q: Does Тразикор interact with common allergy medications?

Official warnings indicate that Тразикор may interact with certain allergy medications known as sympathomimetics, potentially increasing the risk of high blood pressure or heart rate. Furthermore, this medicine may lessen the effectiveness of epinephrine used to treat severe allergic reactions.


Q: Can Тразикор affect vision or cause eye dryness?

Blurred vision is listed in regulatory sources as a less common side effect associated with the use of beta-blockers. Any changes to vision are typically addressed by consulting a healthcare professional.


Q: What are the typical benefits a patient might expect from Тразикор over a few weeks?

The primary therapeutic effects of this medicine are intended to reduce blood pressure and heart rate. While effects on these measures begin relatively quickly, the full stabilization of these parameters is typically observed over a short period of consistent use.


Q: Does exposure to heat or cold affect the effectiveness of Тразикор?

To maintain its stability, the medicine should be stored properly, protected from light and moisture, and kept below 25 C (77 F). Separately, a common side effect is cold extremities, which may be exacerbated by exposure to cold environmental conditions.

Advertisements

How should Тразикор be stored and disposed of?

How to Store and Dispose of Trazicor (Oxprenolol)

The storage and disposal of Trazicor must follow the requirements specified in official regulatory labeling to maintain product stability and ensure public safety.

Storage Requirements

Condition Requirement
Temperature Store below 25 C (77 F).
Protection Keep protected from light and excessive moisture.
Packaging Store in the original container and keep it tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Do not throw away unused or expired Trazicor via wastewater or household waste. Disposal must be carried out according to local requirements. Patients should consult a pharmacist or healthcare professional for guidance on proper disposal procedures for any medication no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Тразикор found in:

A-Z Index: